Literature DB >> 21330602

CD155 on human vascular endothelial cells attenuates the acquisition of effector functions in CD8 T cells.

Nichole K Escalante1, Anna von Rossum, Martin Lee, Jonathan C Choy.   

Abstract

OBJECTIVE: CD155 is a cell surface protein that has recently been described to exert immune regulatory functions. We have characterized the expression of CD155 on human vascular endothelial cells (ECs) and examined its role in the regulation of T-cell activation. METHODS AND
RESULTS: CD155 was expressed on resting human vascular ECs and was upregulated in an interferon-γ (IFNγ)-dependent manner. When the function of CD155 in regulating T-cell activation was examined, antibody-mediated neutralization of CD155 did not affect CD8 T-cell proliferation in response to stimulation with ECs. However, neutralization of CD155 activity or small interfering RNA-mediated inhibition of CD155 expression in ECs increased expression of IFNγ and cytotoxic effector function in activated CD8 T cells.
CONCLUSIONS: CD155 is an IFNγ-inducible immune regulatory protein on the surface of human ECs that attenuates the acquisition of effector functions in CD8 T cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330602     DOI: 10.1161/ATVBAHA.111.224162

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  12 in total

Review 1.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

2.  Positive feedback regulation of human inducible nitric-oxide synthase expression by Ras protein S-nitrosylation.

Authors:  Martin Lee; Jonathan C Choy
Journal:  J Biol Chem       Date:  2013-04-18       Impact factor: 5.157

Review 3.  TIGIT as an emerging immune checkpoint.

Authors:  H Harjunpää; C Guillerey
Journal:  Clin Exp Immunol       Date:  2019-12-25       Impact factor: 4.330

4.  Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer.

Authors:  Satoshi Nishiwada; Masayuki Sho; Satoshi Yasuda; Keiji Shimada; Ichiro Yamato; Takahiro Akahori; Shoichi Kinoshita; Minako Nagai; Noboru Konishi; Yoshiyuki Nakajima
Journal:  J Exp Clin Cancer Res       Date:  2015-03-28

Review 5.  Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis.

Authors:  Anna von Rossum; Ismail Laher; Jonathan C Choy
Journal:  Front Immunol       Date:  2015-01-12       Impact factor: 7.561

6.  Detecting cell-type-specific allelic expression imbalance by integrative analysis of bulk and single-cell RNA sequencing data.

Authors:  Jiaxin Fan; Xuran Wang; Rui Xiao; Mingyao Li
Journal:  PLoS Genet       Date:  2021-03-04       Impact factor: 5.917

Review 7.  Depleting Tumor Cells Expressing Immune Checkpoint Ligands-A New Approach to Combat Cancer.

Authors:  Fabrizio Marcucci; Cristiano Rumio
Journal:  Cells       Date:  2021-04-12       Impact factor: 6.600

8.  CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.

Authors:  Xian-Yang Li; Indrajit Das; Ailin Lepletier; Venkateswar Addala; Tobias Bald; Kimberley Stannard; Deborah Barkauskas; Jing Liu; Amelia Roman Aguilera; Kazuyoshi Takeda; Matthias Braun; Kyohei Nakamura; Sebastien Jacquelin; Steven W Lane; Michele Wl Teng; William C Dougall; Mark J Smyth
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

9.  Changes in the molecular phenotype of nucleus pulposus cells with intervertebral disc aging.

Authors:  Xinyan Tang; Liufang Jing; Jun Chen
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

10.  The Role of T Cell Costimulation via DNAM-1 in Kidney Transplantation.

Authors:  Anna K Kraus; Jin Chen; Ilka Edenhofer; Inga Ravens; Ariana Gaspert; Pietro E Cippà; Steffen Mueller; Rudolf P Wuthrich; Stephan Segerer; Guenter Bernhardt; Thomas Fehr
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.